CN101675080A - ***模拟肽衍生物及其可药用盐和其制备方法与用途 - Google Patents
***模拟肽衍生物及其可药用盐和其制备方法与用途 Download PDFInfo
- Publication number
- CN101675080A CN101675080A CN200880014247A CN200880014247A CN101675080A CN 101675080 A CN101675080 A CN 101675080A CN 200880014247 A CN200880014247 A CN 200880014247A CN 200880014247 A CN200880014247 A CN 200880014247A CN 101675080 A CN101675080 A CN 101675080A
- Authority
- CN
- China
- Prior art keywords
- seq
- derivative
- ala
- mimetic peptide
- epo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 权利要求书:1、 一种通式为(I)的***模拟肽衍生物及其可药用盐,Ri-R2- (C¾) n ~R- (C¾)„2-R4-R6(I)其中 、 R5选自***模拟肽单体肽及其类似物; n,、 n2各自独立地选 自 0〜10的整数; 、 各自独立地选自 - CO或- C ; R3选自 0、S、-C -、N (CH2)„3NHR6、 NC0 (C )„,,NHR6、 CH0C0NH (C )„5NHR6、 CHSC0N (C ) n5NHR6或 CHNHC0N (CH2) n5NH ,其中 n:i选自 1〜10的整数, 选自 2〜10的整数, 选自 2〜10的整数, RB选自 H或甲 氧基聚乙二醇衍生物。2、 根据权利要求 1所述的***模拟肽衍生物及其可药用盐, 其特征在 于 R,、 各自独立的选自通式为 YAX GX^TWX YA的***模拟肽单 体肽或其类似物, 其中该类似物中每个氨基酸均由一个标准单字母表示; 、 、 、 X5 、 Xe、 Y3各自独立的选自 20个遗传性编码的 L-氨基酸或非天然氨基酸中的 任意一个; Υ,、 Υ2各自独立的选自 20个遗传性编码的 L-氨基酸或非天然氨基酸中 任意一个或由这些氨基酸所组成的肽段; XL、 选自 C、 K、 D、 E、 Orn或 Hoc。3、 根据权利要求 2所述的***模拟肽衍生物及其可药用盐, 其特征在 于 R,、 Rs的氨基酸序列是一致的或不一致的。4、 根据权利要求 1〜3任意一项所述的***模拟肽衍生物及其可药用 盐, 其特征在于 R,、 R5的 N末端被乙酰化。 5、 根据权利要求 1〜4任意一项所述的***模拟肽衍生物及其可药用 盐, 其特征在在于 、 为形成二硫键的环肽。6、 根据权利要求 2所述的***模拟肽衍生物及其可药用盐, 其特征在 于¥3选自 K、 11或1?, 优选 ¥3是1^。7、 根据权利要求 1〜6任意一项所述的***模拟肽衍生物及其可药用 盐,其特征在于 R,、 的氨基酸序列的长度为 13〜40个氨基酸, 优选为 22个氨基 酸。 8、 根据权利要求 1〜7任意一项所述的***模拟肽衍生物及其可药用 盐, 其特征在于 、 R5选自具有如下序列 SEQ ID Nol- No30结构的环肽:Ac-GGLYADHYGPITWVKQPLRGGK-NH2(SEQ lDNO:l)Ac-GGLYADHYGPITWV-0rn-QPLRGGK-NH2(SEQ ID NO :2)Ac-GGLYAKHYGPITWVDQPLRGG -NH2(SEQ ID NO :3)Ac-GGLYA-Orn-HYGPlTWVDQPLRGGK-NH2(SEQ ID NO :4)Ac-GGTYSCHFGPLTWVCRPQRG- J3 Ala- K-NH2(SEQ ID NO:5)Ac-GGTYSC-Nle-FGPLTWVCRPQRG- β Ala-K-NH2(SEQ ID NO:6)Ac-GGTYSCHFGSLTWVCRPQRG- β Ala-K-NH2(SEQ ID NO:7)Ac-GGTYSCHFGALTWVCRPQRG- β Ala-K-NH2(SEQ ID NO :8)Ac-GGLYADHYGPMTWVKQPLRGG -NH2(SEQ ID NO :9)Ac-GGLYADHYGPMTWV-Orn-QPLRGGK-NH2(SEQ ID NO:] 0)Ac-GGLYA-Orn-HYGPMTWVDQPLRGG -NH2(SEQ ID NO:l 1)Ac-GGTYSKHFGPMTWVORPQRG- Ala- K-NH2(SEQ ID NO :12)Ac-GGTYSCHFGPITWVCRPQRG- β Ala- K-NH2(SEQ ID NO :13)Ac-GGTYsiHFGPMTWV¾oc-RPQRG- 0 Ala- K-NH2(SEQ ID NO: 14) Ac-GGTYSCHFGPITWV-Hoc-RPQRG- β Ala- K-NH2(SEQ ID NO: 15) Ac-GGTYS(i-Nle-FGPMTWV-lkoc-RPQRG- 0 Ala-K-NH2(SEQ ID NO :16) Ac-GGTYSii- e-FGPITWviRPQRG- β Ala-K-NH2(SEQ ID NO :17)Ac-GGTYSCHFGPLTWVCRPQRG- β Ala-K-NH2(SEQ ID NO: 18)β Ala-K-NH2(SEQ ID NO :19)Ac-GGTYSKHFGSMTWVERPQ G- β Ala-K-NH2(SEQ ID NO:20)Ac-GGTYR(isMGPMTWV0LPMAGGK-NH2(SEQ ID NO :21)AC-GGTYR SMGPLTWV¾LPMAGGK-NH2(SEQ ID NO:22)Ac-GGTYSCHFGAMTWVCRPQRG- β Ala-K-NH2(SEQ ID NO:23)Ac-GGTYSCHFGAITWVCRPQRG- β Ala-K-NH2(SEQ ID NO:24)Ac-GGTYSCHFGPITWVCRPQRG- β Ala-K-NH2(SEQ ID NO :25)AC-GGTYS0HFGPLTWV(1:RPQRG- ^ Ala-K-NH2(SEQ ID NO:26)Ac-GGMYSCRMGPMTWVCGPSRGGK-NH2(SEQ ID NO :27)Ac-GGMYSCRMGPLTWVCGPSRGGK-NH2(SEQ ID NO:28)Ac-GGTYSCHFGPLTWV-Hoc-RPQRG- β Ala- K-NH2(SEQ ID NO :29)或 Ac-GGTYS-Hoc-HFGPLTWVCRPQRG- β Ala- K- H2(SEQ ID NO:30)。 9、 根据权利要求 1〜7任意一项所述的***模拟肽衍生物及其可药用 盐, 其特征在于 R,、 R5各自独立的选自具有如下序列 SEQ ID Nol- No8结构的环肽,Ac-GGLYADHYGPITWV^QPLRGGK-NH2(SEQ ID N0:1)Ac-GGLYADHYGPITWV-Orn-QPLRGGK- H2(SEQ ID NO :2)Ac-GGLYAiHYGPITWV0QPLRGG - H2(SEQ ID NO :3)Ac-GGLYA-Om-HYGPIT VDQPLRGGK-NH2(SEQ ID NO :4)Ac-GGTYSCHFGPLTWVCRPQ G- β Ala- K-NH2(SEQ ID NO: 5)Ac-GGTYsi-Nle-FGPLTWviRPQRG- β Ala-K- H2(SEQID NO :6)Ac-GGTYSCHFGSLTWVCRPQRG- & Ala-K-NH2(SEQ ID NO:7)或Ac-GGTYSCHFGALTWVCRPQRG- β Ala-K-爾 2(SEQ ID NO :8)。 10、根据权利要求 1〜9任意一项所述的***模拟肽衍生物及其可药用 盐, 其特征在于所述的***模拟肽衍生物选自下列肽, 其中ru,n2是 2, R2、 是 C0, 是 CH0C0NH (C¾) n5NH , 是2;nb 是 1, R2、 是- CO, R3是 NC0 (C¾) n4NHR6) 是 2;是2, R2、 R4是- (¾, 是 CH0C0NH (CH2) n5NHR6, n5是 2; 或者, 是1, R2、 C ,R3是 Ν∞((¾) η4ΝΗ , η4是 2。11、根据权利要求 10任意一项所述的***模拟肽衍生物及其可药用盐, 其特征在于!^是!"!。 12、根据权利要求 10任意一项所述的***模拟肽衍生物及其可药用盐, 其特征在于 R6是甲氧基聚乙二醇衍生物, 优选甲氧基聚乙二醇衍生物分子量为 5, 000〜100, 000道尔顿。13、 根据权利要求 12所述的***模拟肽衍生物及其可药用盐, 其特征 在于所述的甲氧基聚乙二醇衍生物的结构为分枝型或线型, 优选甲氧基聚乙二醇 衍生物的结构为线型、 分子量为 20, 000道尔顿, 或者甲氧基聚乙二醇衍生物的 结构为分枝型、 分子量为 40, 000道尔顿。14、 根据权利要求 1〜13任意一项所述的***模拟肽衍生物及其可药 用盐,其特征在于所述的***模拟肽衍生物选自下列肽, 其中, 是 2, R(、 选自序列350 10 :1〜380:0^0: 8, 、 选自- C0或一 CH2, R3 是 CH0C0NH (CH2)„5NHR6,其中 选自 2〜10的整数; R6是结构为线型、分子量为 20, 000道尔顿的甲氧基聚乙二醇衍生物;r ,n2是 1, R5选自序列SEQIDN0:1〜SEQIDN0:8, R2、 选自- CO或一 C R3 是 NC0(CH , ,其中 选自 2〜10的整数; 是结构为线型、分子量为 20, 000 道尔顿的甲氧基聚乙二醇衍生物;n n2是 2, 、 R5选自序列 SEQ ID 1〜SEQ ID 8, R2、 R„选自- CO或一 CH2, R3是 CH0C0NH(C¾)n5NHRe, 其中 n5选自 2〜10的整数; 是结构为分枝型、分子量为 40, 000道尔顿的甲氧基聚乙二醇衍生物; 或者n n2是 1, 、 R5选自序列 SEQIDN0:1〜SEQIDN0:8, R2、 R4选自- CO或一 C¾, R3 ?¾NC0(C¾)n,NHR6, 其中 选自 2〜10的整数; 是结构为分枝型、 分子量为 40, 000道尔顿的甲氧基聚乙二醇衍生物。15、 根据权利要求 1〜14任意一项所述的***模拟肽衍生物及其可药 用盐, 其特征在于所述的***模拟肽衍生物及其可药用盐为20v)IGSAo(3OJla≥AVV de2MU0 I- 16、一种制备权利要求 1〜15任意一项所述的***模拟肽衍生物及其 可药用盐的方法, 包括以下歩骤:(1)制备 R,H、 R5H, 其中 R,、 R5选自***模拟肽单体肽及其类似物,(2)制备通式为 (Π) 的功能小分子RT-C0- (CH2)„-Z2- (C ) n2-C0-R8(II)其中 n,、 各自独立地选自 0〜10的整数;R7、 R8选自 OH或 H;.Z2选自 0、 S、 C 、 N (CH2) n6NHR9、 NCO (C )„7NHR9、 CH0C0NH (C )„8NHR9、 CHSC0N (CH2) η8ΝΗ¾ 或 CHNHC0N(C )n8NHRa, 其中 为选自 1〜10的整数, n7为选自 2〜10的整数, 为选自 2〜10的整数, Rg选自 Boc或 Cbz,(3)将 Rt、 与通式为 (II) 的功能小分子进行酰胺化反应或还原胺化反应, 制 备得通式 (III) 化合物,R「R CH2)NL- Z2 (CH 2- (111),其中 R2、 各自独立地选自- CO或 - C¾,(4)脱去 Boc或 Cbz后, 与活性甲氧基聚乙二醇衍生物进行酰胺化反应。17、 根据权利要求 16所述的制备方法, 其特征在于所述的通式 (II) 中, r、 是 1或 2, R7、 R8选自 0H , Z2选自 。((^ ^!!!^或 CH0C0NH(C )n8NHR9, n7 选自 2~10的整数, 选自 2〜10的整数, 是 Boc; 或者、 是 1或 2, R7、 R8选自 H , Z2选自 NC0(C )n7NHR9或 CH0C0NH(CH2) n8NHR9, n7 选自 2〜10的整数, 选自 2〜10的整数, 是80 18、 一种药物组合物, 包含:(1)治疗量的如权利要求 1〜15任一项所述的***模拟肽衍生物及其 可药用盐, 和(2)药学可接受的药物载体。 19、 根据权利要求 1〜15 中任一项所述的***模拟肽衍生物及其可药 用盐在制备用于治疗以缺乏红细胞生成素或红细胞群缺少或缺陷为特征的疾病的 药物中的用途。20、根据权利要求 18所述的药物组合物在制备用于治疗以缺乏红细胞生成素或红 细胞群缺少或缺陷为特征的疾病的药物中的用途。 21、 根据权利要求 19或 20所述的用途, 其特征在于所述缺乏红细胞生成素或红 细胞群缺少或缺陷为特征的疾病是末期肾功能衰竭或透析; AIDS相关性贫血, 自 身免疫性疾病, 或恶性肿瘤; 囊性纤维变性; 早期早熟性贫血; 与慢性炎性疾病 相关的贫血; 脊髓损伤; 急性失血; 衰老和伴有异常红细胞产生的肿瘤疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008800142471A CN101675080B (zh) | 2007-12-12 | 2008-11-24 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200710198751.9 | 2007-12-12 | ||
CNA2007101987519A CN101456911A (zh) | 2007-12-12 | 2007-12-12 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
CN2008800142471A CN101675080B (zh) | 2007-12-12 | 2008-11-24 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
PCT/CN2008/001909 WO2009079910A1 (en) | 2007-12-12 | 2008-11-24 | An erythropoietin mimetic peptide derivatives and its pharmaceutical salt, the preparation and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101675080A true CN101675080A (zh) | 2010-03-17 |
CN101675080B CN101675080B (zh) | 2012-07-11 |
Family
ID=40768057
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101987519A Pending CN101456911A (zh) | 2007-12-12 | 2007-12-12 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
CN2008800142471A Active CN101675080B (zh) | 2007-12-12 | 2008-11-24 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007101987519A Pending CN101456911A (zh) | 2007-12-12 | 2007-12-12 | ***模拟肽衍生物及其可药用盐和其制备方法与用途 |
Country Status (16)
Country | Link |
---|---|
US (1) | US8642545B2 (zh) |
EP (1) | EP2233504B1 (zh) |
JP (1) | JP5448099B2 (zh) |
KR (1) | KR101646929B1 (zh) |
CN (2) | CN101456911A (zh) |
AU (1) | AU2008341661B9 (zh) |
BR (1) | BRPI0820749B8 (zh) |
CA (1) | CA2708819C (zh) |
ES (1) | ES2541139T3 (zh) |
HK (1) | HK1136837A1 (zh) |
MX (1) | MX2010006436A (zh) |
RU (1) | RU2493168C2 (zh) |
TW (1) | TWI419706B (zh) |
UA (1) | UA102236C2 (zh) |
WO (1) | WO2009079910A1 (zh) |
ZA (1) | ZA201003998B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570834A (zh) * | 2012-07-19 | 2014-02-12 | 江苏豪森药业股份有限公司 | 甲氧基聚乙二醇修饰的***模拟肽衍生物 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2709648A4 (en) * | 2011-05-19 | 2015-04-08 | Geysen Hendrik M | COMPOUNDS FOR BINDING TO THE ERYTHROPOIETIN RECEPTOR |
WO2013158871A1 (en) | 2012-04-20 | 2013-10-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of erythropoietin and derivatives for treating hypertension |
CN103450348B (zh) * | 2012-05-29 | 2016-03-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种***模拟肽、其制备方法和用途 |
CN103536900B (zh) * | 2012-07-16 | 2017-06-16 | 江苏豪森药业集团有限公司 | 含有***模拟肽的药物组合物 |
WO2014149477A1 (en) | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for achieving therapeutically effective doses of anti-cd47 agents |
CN104231039A (zh) * | 2013-06-08 | 2014-12-24 | 江苏豪森药业股份有限公司 | 用于合成***模拟肽衍生物的功能小分子及其制备方法 |
CN105085653B (zh) * | 2015-08-26 | 2019-01-08 | 天津药物研究院有限公司 | 一种***模拟肽及其制备方法和应用 |
CN106608913B (zh) * | 2015-10-22 | 2020-05-05 | 天津药物研究院有限公司 | 一种1,2,3-丙三酸偶联的epo拟肽衍生物及其制备方法和应用 |
CN106608912B (zh) * | 2015-10-22 | 2019-09-20 | 天津药物研究院有限公司 | 一种脂肪二羧酸偶联的epo模拟肽衍生物及其制备方法和应用 |
CN105367629B (zh) * | 2015-11-09 | 2019-01-08 | 天津药物研究院有限公司 | 一种***模拟肽以及其制备方法和用途 |
CN106928338A (zh) * | 2015-12-31 | 2017-07-07 | 杭州阿德莱诺泰制药技术有限公司 | ***肽及衍生物和聚合物、制备方法和应用 |
KR20230048469A (ko) | 2016-07-12 | 2023-04-11 | 헥살 아게 | 시알산 잔기의 감소된 아세틸화율을 갖는 당단백질 |
CN108236717A (zh) * | 2016-12-27 | 2018-07-03 | 江苏豪森药业集团有限公司 | 聚乙二醇连接臂与所修饰多肽药物的偶合物 |
KR102073886B1 (ko) | 2019-05-02 | 2020-02-05 | 주식회사 미래와바다 | 잘피이식용 다공질 패널 |
CN114601916B (zh) * | 2022-04-12 | 2024-04-16 | 江苏豪森药业集团有限公司 | 一种培化西海马肽注射制剂及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990008822A1 (en) | 1989-02-03 | 1990-08-09 | Genetics Institute, Inc. | Erythropoietin receptor |
JP4050314B2 (ja) * | 1995-06-07 | 2008-02-20 | オーソ ファーマシューティカル コーポレイション | エリトロポエチン受容体に結合する化合物およびペプチド |
EP0964702B1 (en) | 1996-08-02 | 2006-10-04 | Ortho-McNeil Pharmaceutical, Inc. | Polypeptides having a single covalently bound n-terminal water-soluble polymer |
ATE291436T2 (de) * | 2000-05-15 | 2005-04-15 | Hoffmann La Roche | Flüssige arzneizubereitung enthaltend ein erythropoietin derivat |
CN1169827C (zh) * | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
AU2004238870B8 (en) | 2003-05-12 | 2010-04-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
MXPA05012315A (es) | 2003-05-12 | 2006-04-18 | Affymax Inc | Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos. |
SI1625156T1 (sl) | 2003-05-12 | 2013-02-28 | Affymax, Inc. | Peptidi, ki se veĹľejo k eritropoetinskemu receptorju |
CN100362019C (zh) * | 2004-03-02 | 2008-01-16 | 成都生物制品研究所 | 聚乙二醇修饰后具有体内生理活性的重组*** |
WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
US20090005292A1 (en) * | 2004-11-11 | 2009-01-01 | Affymax, Inc. | Novel Peptides that Bind to the Erythropoietin Receptor |
-
2007
- 2007-12-12 CN CNA2007101987519A patent/CN101456911A/zh active Pending
-
2008
- 2008-07-08 TW TW097125651A patent/TWI419706B/zh active
- 2008-11-24 RU RU2010123466/10A patent/RU2493168C2/ru active
- 2008-11-24 ES ES08865748.1T patent/ES2541139T3/es active Active
- 2008-11-24 UA UAA201007321A patent/UA102236C2/uk unknown
- 2008-11-24 MX MX2010006436A patent/MX2010006436A/es active IP Right Grant
- 2008-11-24 US US12/747,818 patent/US8642545B2/en active Active
- 2008-11-24 CA CA2708819A patent/CA2708819C/en active Active
- 2008-11-24 AU AU2008341661A patent/AU2008341661B9/en active Active
- 2008-11-24 CN CN2008800142471A patent/CN101675080B/zh active Active
- 2008-11-24 EP EP08865748.1A patent/EP2233504B1/en active Active
- 2008-11-24 WO PCT/CN2008/001909 patent/WO2009079910A1/zh active Application Filing
- 2008-11-24 JP JP2010537234A patent/JP5448099B2/ja not_active Expired - Fee Related
- 2008-11-24 BR BRPI0820749A patent/BRPI0820749B8/pt active IP Right Grant
- 2008-11-24 KR KR1020107014960A patent/KR101646929B1/ko active IP Right Grant
-
2010
- 2010-05-11 HK HK10104545.0A patent/HK1136837A1/xx unknown
- 2010-06-04 ZA ZA2010/03998A patent/ZA201003998B/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103570834A (zh) * | 2012-07-19 | 2014-02-12 | 江苏豪森药业股份有限公司 | 甲氧基聚乙二醇修饰的***模拟肽衍生物 |
Also Published As
Publication number | Publication date |
---|---|
AU2008341661B2 (en) | 2013-08-08 |
CN101675080B (zh) | 2012-07-11 |
CA2708819C (en) | 2018-05-15 |
EP2233504A1 (en) | 2010-09-29 |
BRPI0820749B8 (pt) | 2021-05-25 |
KR101646929B1 (ko) | 2016-08-09 |
BRPI0820749B1 (pt) | 2020-11-24 |
TW201002352A (en) | 2010-01-16 |
WO2009079910A1 (en) | 2009-07-02 |
WO2009079910A8 (zh) | 2009-11-19 |
BRPI0820749A2 (pt) | 2015-06-16 |
EP2233504B1 (en) | 2015-04-01 |
MX2010006436A (es) | 2010-10-06 |
TWI419706B (zh) | 2013-12-21 |
EP2233504A4 (en) | 2011-03-09 |
CA2708819A1 (en) | 2009-07-02 |
JP5448099B2 (ja) | 2014-03-19 |
ZA201003998B (en) | 2011-10-26 |
UA102236C2 (uk) | 2013-06-25 |
AU2008341661A1 (en) | 2009-07-02 |
HK1136837A1 (en) | 2010-07-09 |
AU2008341661B9 (en) | 2013-08-15 |
KR20110025731A (ko) | 2011-03-11 |
ES2541139T3 (es) | 2015-07-16 |
US8642545B2 (en) | 2014-02-04 |
RU2493168C2 (ru) | 2013-09-20 |
RU2010123466A (ru) | 2012-01-20 |
CN101456911A (zh) | 2009-06-17 |
JP2011506350A (ja) | 2011-03-03 |
US20100323949A1 (en) | 2010-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101675080A (zh) | ***模拟肽衍生物及其可药用盐和其制备方法与用途 | |
CN105899529A (zh) | 胰高血糖素类似物 | |
CN103536900B (zh) | 含有***模拟肽的药物组合物 | |
CA3180215A1 (en) | Dual-agonist compound for both glp-1 and gip receptors and application thereof | |
CN117098770A (zh) | 针对sort1的多肽化合物及其药物偶联物 | |
CN110746490A (zh) | 一种基于点击反应阻断免疫检查点的多肽组合物及其制备方法和应用 | |
CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
TW201002350A (en) | Polyethylenenized erythropoietin conjugate, preparation thereof and its use | |
TWI565714B (zh) | 非肽基聚合物-胰島素集合體及其製造方法 | |
CN117015551B (zh) | 多肽的制备及其应用 | |
CN105085653B (zh) | 一种***模拟肽及其制备方法和应用 | |
CN110498860A (zh) | 一种具有抗肿瘤功能的融合蛋白及其制备方法和应用 | |
JPWO2010074082A1 (ja) | バソヒビン修飾体 | |
CN113024635B (zh) | 一类订书肽化合物及其药物组合物的用途 | |
CN105367629B (zh) | 一种***模拟肽以及其制备方法和用途 | |
CN105837681B (zh) | 一种***模拟肽衍生物、其制备方法和用途 | |
CN106554395B (zh) | 一种长效***模拟肽及其制备方法和应用 | |
CN117567564A (zh) | 一种多肽衍生物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136837 Country of ref document: HK |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1136837 Country of ref document: HK |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: JIANGSU HANSOH PHARMACEUTICAL GROUP Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: Jiangsu best Pharmaceutical Co.,Ltd. Address after: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee after: Jiangsu best Pharmaceutical Co.,Ltd. Address before: Tenth Industrial Zone, Lianyungang, Jiangsu, China, 222047 Patentee before: JIANGSU HANSOH PHARMACEUTICAL Co.,Ltd. |